What "medical" covers in the AngelMatch database
The medical tag is broad on purpose. It pulls in angel investors, venture capitalists and private equity investors who back everything from digital health platforms to medical devices, biotech and life sciences startups. That is useful when you are casting a wide net early, but it also means you will see some overlap with the health care, digital health and biotechnology lists. If your product is a physical device rather than software or a therapeutic, the medical devices list is often a tighter fit, and it's worth pulling both lists and comparing before you commit to outreach.
There are 15,000+ investors tagged to medical in AngelMatch right now, and the database updates regularly, so treat that as a floor rather than a fixed number. Most of them write checks as venture capitalists or private equity investors, with a smaller but active pool of individual angels rounding out the list.
Where medical investors are based
Well over half of medical investors in the database are based in the United States, and the concentration inside the US is even tighter than that. If you filter by state, California and New York carry the biggest numbers, with 2,000+ and 1,500+ respectively. Massachusetts, home to the Boston and Cambridge biotech corridor, holds 850+. Outside the US, the United Kingdom is the clearest second market with 1,000+ medical investors, most of them clustered in London.
At the city level, New York City and San Francisco each carry 1,000+ medical investors, followed by London at 600+ and Boston at 550+. If you're deciding where to spend your travel budget on in-person pitches, those four cities cover a large share of the people who will actually write the check. A founder in Chicago or Austin isn't excluded from any of this, but the density of warm intros and investor events tilts heavily toward the coasts and Boston.
Beyond the UK, France, Germany, China and Canada round out the next tier of markets, each holding a few hundred medical investors. None of them comes close to the US or UK on volume, but they're worth checking if you're building for a specific regional health system or planning to expand into that market, since local investors tend to bring the regulatory and distribution relationships that matter most in medical.
What stage medical investors fund
Seed is the single biggest stage tag in the medical list at 3,500+, with early stage venture close behind at 2,500+. About two in five medical investors in the database are tagged to one of those two stages, which tells you where the bulk of first checks come from. Series A pulls 1,000+, pre-seed sits at 850+ and Series B drops to 750+, the usual falloff as fewer investors are willing to write bigger, later checks into a narrower field.
The practical read: if you're pre-product or pre-revenue, you have real company in the medical space. If you're already at Series B, your list gets meaningfully shorter, and the investors left on it tend to be more selective about traction and regulatory milestones before they'll engage.
What medical investors are prioritizing right now
US digital health startups raised $7.4 billion across 244 deals in the first half of 2026, up from $6.4 billion in the same period a year earlier, according to Rock Health. That growth is concentrated, not spread out. Mega deals of $100 million or more made up 45% of all capital invested in the first half of the year, up sharply from 22% back in 2024. That means a shrinking number of standout companies are absorbing a growing share of the dollars, while everyone else is competing for what's left.
Mental health has been the top-funded clinical category for seven straight years, and weight management is now a close second, largely riding the GLP-1 wave. Both categories skew heavily toward direct-to-consumer business models. If you're building in either space, lead your pitch with your customer acquisition numbers and unit economics, not just your clinical thesis, because that's what the investors funding those deals are actually underwriting right now.
Investors backing medical startups are also placing more weight on the founding team's domain background than they used to. As AI makes it easier for almost anyone to spin up a health product, the investors funding the strongest rounds say they're looking for founders who've actually worked inside the systems they're trying to sell into, whether that's a hospital, a payer or a clinical practice. If you or a co-founder have that kind of operating experience, put it high in your deck rather than treating it as a footnote in your bio slide.
Who's writing the checks
Venture capitalists make up the largest single group at 10,000+, with private equity investors close behind at 9,500+. Those two groups do the bulk of institutional investing in medical, but they're rarely the right first call for a founder without any traction. Individual angels at 4,000+ and micro VCs at 1,000+ are typically the faster, lower-friction checks for a seed or pre-seed round, since they move without the committee process a larger fund needs. Investment partners, at 1,000+, tend to sit inside larger funds and are often a useful secondary contact once you already have a lead investor interested.
If you're early and moving fast, start your outreach with angels and micro VCs rather than going straight for the biggest venture capital names on the list. You'll get faster answers, and a small early check from a credible medical investor often makes the bigger funds easier to close later.
Check sizes and dilution
Angel investors in medical, as in most categories on AngelMatch, typically write checks between $25,000 and $500,000. Venture capitalists write much larger checks, from $2 million up to $100 million or more depending on the stage and how competitive the round gets. Expect dilution of roughly 15% to 25% at an early round, and don't let a term sheet that falls well outside that band go unquestioned.
Because the medical list spans everything from a first angel check to a $100 million growth round, it helps to filter by stage before you start building your outreach list in the investor database, rather than working through all 15,000+ names in order.
How to reach medical investors
Medical investors move on evidence, not enthusiasm. A generic "we're disrupting healthcare" opener gets deleted. What gets a reply is a specific data point: a completed study, a signed pilot with a health system, a regulatory milestone hit on schedule or early revenue with a named payer. Put that in the first two lines of your email, not buried in an attached deck.
Timing matters more here than in most categories. The JPMorgan Healthcare Conference every January pulls a large share of active medical investors into one week of meetings, and the weeks immediately before and after it are when inboxes are most primed for healthcare pitches. The last two weeks of December, by contrast, go quiet as investors close out the year, so save your best outreach for January rather than squeezing it in before the holidays. Keep your pipeline organized in a fundraising CRM so you can track who you've reached and when to follow up, especially if you're running outreach across a list this size.
Medical investors also read pitch decks differently than generalist investors. They expect a clinical or regulatory slide up front, not buried at the back, and they'll skim past anything that reads like a consumer app pitch dressed up in healthcare language. Hosting your deck somewhere you can see who's opened it and how far they got helps you know who's actually engaged, not just replying politely.
The medical investors most likely to move quickly are the ones already tagged to your specific sub-sector and stage, not the full 15,000+ list. Start with the seed and early-stage names in your city or region, layer in the health care and digital health lists for names the medical tag alone might miss and build your outreach around the evidence your company actually has today rather than what you hope to have by the next round.
Health care investors
